Welcome to our dedicated page for Assembly Bioscie news (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Bioscie stock.
Assembly Biosciences, Inc. (ASMB) is a clinical-stage biotechnology leader advancing innovative oral therapies for hepatitis B virus (HBV) and microbiome-related disorders. This news hub provides investors and researchers with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access authoritative reporting on ASMB's antiviral research programs and microbiome therapeutic platforms. Our curated news collection features press releases covering clinical trial progress, partnership announcements, and scientific presentations - all essential for informed analysis of the company's pipeline.
Key focus areas include updates on HBV core inhibitor candidates, microbiome strain development, and intellectual property advancements. Content is rigorously verified to ensure compliance with financial disclosure standards while maintaining scientific accuracy.
Bookmark this page for direct access to primary source materials and objective reporting on ASMB's pioneering work in oral antiviral therapies. Check regularly for the latest developments in this dynamic sector of precision medicine.
Assembly Biosciences (Nasdaq: ASMB) has announced the pricing of two equity financings totaling $175 million. The company is conducting an underwritten public offering of 5,591,840 shares of common stock and 1,040,820 pre-funded warrants, along with accompanying Class A and Class B warrants, at $19.60 per share.
Additionally, Gilead Sciences will participate through a private placement, purchasing 2,295,920 shares with accompanying warrants. Notable investors include Commodore Capital, Blackstone Multi-Asset Investing, Farallon Capital Management, Janus Henderson Investors, and RA Capital Management. The transactions are expected to close on August 11, 2025.
Assembly Biosciences (NASDAQ:ASMB) reported positive interim results from its Phase 1b study of ABI-5366, a long-acting helicase-primase inhibitor for recurrent genital herpes. The 350mg weekly oral dose demonstrated remarkable efficacy with a 94% reduction in HSV-2 shedding rate and genital lesion rate compared to placebo over a 29-day period.
Key highlights include a 98% reduction in high viral load shedding rate and favorable safety profile. The pharmacokinetic profile supports potential for both weekly and monthly dosing regimens. Assembly Bio plans to advance directly to Phase 2 clinical studies, expected to initiate in mid-2026.
Under their collaboration agreement, Gilead Sciences maintains the right to opt in for exclusive licensing following completion of Phase 1b studies.
Assembly Biosciences (NASDAQ: ASMB) reported Q2 2025 financial results and clinical progress across its viral disease pipeline. The company ended Q2 with $75.0 million in cash, projecting operations funding into mid-2026. Revenue from Gilead collaboration increased to $9.6 million, while net loss improved to $10.2 million ($1.33 per share).
Key clinical developments include: positive Phase 1b results for ABI-4334 in chronic HBV patients, interim data from ABI-6250's Phase 1a study showing target engagement for HDV treatment, and advancement of ABI-5366 and ABI-1179 trials for genital herpes, with proof-of-concept data expected by fall 2025. The company initiated U.S. site expansion for ABI-1179's Phase 1b trial following IND clearance.
Assembly Biosciences (Nasdaq: ASMB) has reported promising interim Phase 1a data for ABI-6250, their oral hepatitis delta virus (HDV) entry inhibitor candidate. The study demonstrated a four-day half-life, supporting once-daily oral dosing, and showed dose-dependent elevations in total serum bile acids, indicating effective target engagement.
Key findings include successful completion of two single-dose cohorts (5mg and 25mg) and three multiple-dose cohorts (0.05mg, 0.2mg, and 1mg). Safety data showed mostly Grade 1 adverse events, with one Grade 2 ALT elevation in the highest dose cohort. All ALT elevations were self-limited without signs of liver injury.
The company plans to conduct additional pharmacological assessment while preparing for Phase 2 studies, positioning ABI-6250 as potentially the first oral therapy for chronic HDV infection.
Assembly Biosciences (NASDAQ:ASMB) presented Phase 1a clinical data for two novel herpes simplex virus (HSV) treatments, ABI-5366 and ABI-1179, at the STI & HIV 2025 World Congress and International Herpesvirus Workshop. The drug candidates, designed as helicase-primase inhibitors, demonstrated promising safety and pharmacokinetic profiles in healthy participants.
Key highlights include the potential for once-weekly dosing for both treatments, and once-monthly dosing for ABI-5366, representing a significant improvement over current daily dosing requirements. Both candidates showed no clinically significant food effects and are now advancing to Phase 1b trials, with interim proof-of-concept data expected in fall 2025.
Assembly Biosciences (Nasdaq: ASMB) has initiated the Phase 1b portion of its Phase 1a/b clinical trial for ABI-1179, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor. The study will evaluate weekly oral doses over 29 days in participants with recurrent genital herpes, focusing on safety and antiviral activity.
The company reported that ABI-1179 demonstrated promising Phase 1a results, showing a pharmacokinetic profile supporting once-weekly oral dosing and low nanomolar potency against both HSV-1 and HSV-2 in vitro. Assembly Bio has received IND clearance to expand the study to U.S. sites.
Notably, Assembly Bio is conducting concurrent Phase 1b studies for both ABI-1179 and ABI-5366, with interim data expected in fall 2025. Under a collaboration agreement, Gilead Sciences maintains the right to opt in for an exclusive license for further development and commercialization of both candidates following review of the Phase 1b data package.
Assembly Biosciences (NASDAQ:ASMB) announced positive topline results from its Phase 1b clinical trial of ABI-4334, a next-generation capsid assembly modulator (CAM) for chronic hepatitis B virus treatment. The trial evaluated two dosage cohorts: 150mg and 400mg daily over 28 days.
Key findings include mean HBV DNA reductions of 2.9 and 3.2 log10 IU/mL in the 150mg and 400mg cohorts respectively. The drug demonstrated favorable safety and tolerability profiles, with pharmacokinetics supporting once-daily oral dosing. The 150mg dose achieved saturated inhibition of viral replication, while the 400mg dose reached exposure levels targeting inhibition of cccDNA formation.
The trial completion triggers Gilead Sciences' opt-in opportunity for an exclusive license to further develop and commercialize ABI-4334.
Assembly Biosciences (NASDAQ: ASMB), a biotechnology company focused on developing therapeutics for viral diseases, has announced its participation in the upcoming Jefferies 2025 Global Healthcare Conference. CEO and President Jason Okazaki, along with Chief Medical Officer Dr. Anuj Gaggar, will engage in a fireside chat on June 4, 2025, at 8:45 a.m. ET. The presentation will be accessible via live webcast on the company's website, with a replay available afterward through their investor relations portal.
Syndeio Biosciences has launched with over $90 million in funding to develop synapse-targeted neurotherapeutics. The company's lead candidate, zelquistinel, is currently in Phase 2 trials for major depressive disorder and will soon begin trials for Alzheimer's disease. The company is backed by prominent investors including Catalio Capital Management, Innoviva, with AbbVie and Lilly as strategic shareholders.
The company's leadership includes experienced neurotherapeutics entrepreneurs and Nobel Laureate Thomas C. Südhof. Their proprietary Boost™ Synapse Pharmacology Platform integrates various models to predict treatment outcomes for synaptogenic agents. Additionally, Syndeio is advancing apimostinel, another investigational therapy for acute MDD treatment, in a Phase 2a study with the University of Pittsburgh.
FAQ
What is the current stock price of Assembly Bioscie (ASMB)?
What is the market cap of Assembly Bioscie (ASMB)?
